The increased use of INSTI based regimens over PI or NNRTI based regimens is largely due to the potency and safety of INSTIs. Case reports of new-onset or worsening of neuropsychiatric conditions, particularly depression and suicidality, have emerged with INSTIs. These reports prompted FDA to investigate the relationship between INSTIs and neuropsychiatric adverse events (NPAE), and compare the frequency of NPAEs with INSTIs, PIs and EFV.
FDA conducted a meta-analysis of 6 randomized, active-controlled Phase 3 trials in treatment-naïve subjects (TN) comparing raltegravir, dolutegravir or elvitegravir to: EFV, PIs (atazanavir or darunavir) or another INSTI. These trials were submitted by industry to FDA to support approval of the INSTIs. The frequency of NPAEs in each treatment group was assessed over 96 weeks. NPAEs were identified using the Standardized MedDRA Query (SMQ) Version 18.0. A broad search for terms in the Depression and Suicide/Self-Injury (DSS) SMQ and the Psychosis and Psychotic Disorders (PPD) SMQ was done. The event of highest toxicity grade was counted for each subject. Overall risk difference for INSTI vs EFV and INSTI vs PI was computed based on fixed effects and random effect analyses using inverse variance weights in both models. In the random effects model (DerSimonian-Laird estimate), the study variable was included as a random effect. Analyses were also performed by demographic subgroups (age, sex, race, region, and IV drug use).
The meta-analysis (primary analysis) shows the risk of NPAE in TN patients was similar for INSTI vs EFV and INSTI vs PI. Risk difference (95% CI) for DSS AEs and PPD AEs: INSTI vs EFV -3% (-5,0) and -1% (-2,1) and INSTI vs PI -1% (-2,4) and 0% (-2,1). Results were identical for the fixed and random effects analyses. Grade 3 and 4 events occurred in 1% of INSTI and PI subjects and 2% of EFV. Subgroup analyses were not interpretable due to small sample size.
This meta-analysis shows the risk of NPAE when analyzed at the level of pooled DSS and PPD SMQs is similar for INSTIs vs EFV, with a trend toward lower risk with INSTIs compared with EFV. The risk for NPAEs is similar between INSTIs and PIs. Although NPAEs were infrequent and risk was not increased with INSTIs, providers should be aware of the association between HIV infection, ART, and NPAEs.